1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
- Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study : high white blood cell count at diagnosis is the strongest prognostic factor
- 2018
- Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
- Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010) : a prospective, intergroup, open-label, single-arm clinical trial
- 2014
- Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
- Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study
- 2013
- Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries
- 2012
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
- 2011
- Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study
- 2010
- Myeloid Leukemia of Down Syndrome The Results of An International Retrospective Study